The shares are down 9%, or $5.53, to $56.94 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $183 from $202 at Needham
- Sarepta study pause brings approvability risk in Europe, says RBC
- Sarepta clinical hold in Europe likely temporary, says Mizuho
- EMA put clinical hold on Roche, Sarepta DMD studies after death
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Trial Hold and Strong Market Position